Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Year Study To Evaluate The Effects Of GPI 1485 On [123I]b-CIT/SPECT Scanning And Clinical Efficacy In Symptomatic PD Patients Receiving Dopamine Agonist Therapy.

Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Year Study To Evaluate The Effects Of GPI 1485 On [123I]b-CIT/SPECT Scanning And Clinical Efficacy In Symptomatic PD Patients Receiving Dopamine Agonist Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2009

At a glance

  • Drugs GM 1485 (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors MGI GP
  • Most Recent Events

    • 05 Nov 2008 Sponsor and affiliate changed from MGI Pharma to Eisai Medical Research, based on information from ClinicalTrials.gov.
    • 14 Oct 2008 Checked against ClinicalTrials.gov record.
    • 02 Nov 2006 Results have been reported.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top